Daniël De Vos

8.0k total citations · 1 hit paper
84 papers, 5.1k citations indexed

About

Daniël De Vos is a scholar working on Ecology, Molecular Biology and Plant Science. According to data from OpenAlex, Daniël De Vos has authored 84 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Ecology, 34 papers in Molecular Biology and 18 papers in Plant Science. Recurrent topics in Daniël De Vos's work include Bacteriophages and microbial interactions (43 papers), Antibiotic Resistance in Bacteria (17 papers) and Bacterial biofilms and quorum sensing (14 papers). Daniël De Vos is often cited by papers focused on Bacteriophages and microbial interactions (43 papers), Antibiotic Resistance in Bacteria (17 papers) and Bacterial biofilms and quorum sensing (14 papers). Daniël De Vos collaborates with scholars based in Belgium, United Kingdom and United States. Daniël De Vos's co-authors include Jean‐Paul Pirnay, Gilbert Verbeken, Pierre Cornélis, Martin Zizi, Mario Vaneechoutte, Maia Merabishvili, Serge Jennes, Rob Lavigne, Isabelle Huys and A. Vanderkelen and has published in prestigious journals such as PLoS ONE, Applied and Environmental Microbiology and Clinical Infectious Diseases.

In The Last Decade

Daniël De Vos

84 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phage Therapy in Clinical Practice: Treatment of Human Infections

2010 496 citations Daniël De Vos et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniël De Vos Belgium	39	3.1k	2.1k	1.3k	1.1k	907	84	5.1k
Jean‐Paul Pirnay Belgium	47	4.7k 1.5×	2.7k 1.3×	2.0k 1.5×	1.4k 1.3×	1.1k 1.2×	133	6.9k
Elizabeth Kutter United States	46	5.6k 1.8×	2.9k 1.4×	1.8k 1.4×	509 0.5×	978 1.1×	77	6.8k
Jeremy J. Barr Australia	27	3.4k 1.1×	1.8k 0.9×	902 0.7×	433 0.4×	668 0.7×	68	4.6k
Daniel Nelson United States	35	2.9k 0.9×	2.3k 1.1×	1.0k 0.8×	349 0.3×	503 0.6×	102	5.1k
Lucía Fernández Spain	36	1.5k 0.5×	2.3k 1.1×	947 0.7×	1.5k 1.4×	496 0.5×	104	5.0k
Stephen T. Abedon United States	50	7.8k 2.5×	3.0k 1.4×	2.8k 2.1×	695 0.6×	1.8k 2.0×	96	8.9k
José R. Penadés Spain	55	3.4k 1.1×	6.4k 3.1×	1.6k 1.2×	789 0.7×	629 0.7×	126	10.0k
Craig Winstanley United Kingdom	46	1.4k 0.4×	3.8k 1.8×	574 0.4×	2.1k 1.9×	1.1k 1.2×	155	7.2k
Nouri L. Ben Zakour Australia	28	1.3k 0.4×	2.2k 1.1×	574 0.4×	1.8k 1.7×	454 0.5×	49	5.6k
Mikael Skurnik Finland	57	2.4k 0.8×	3.8k 1.8×	1.1k 0.8×	653 0.6×	520 0.6×	255	10.3k

Countries citing papers authored by Daniël De Vos

Since Specialization

Citations

This map shows the geographic impact of Daniël De Vos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniël De Vos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniël De Vos more than expected).

Fields of papers citing papers by Daniël De Vos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniël De Vos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniël De Vos. The network helps show where Daniël De Vos may publish in the future.

Co-authorship network of co-authors of Daniël De Vos

This figure shows the co-authorship network connecting the top 25 collaborators of Daniël De Vos. A scholar is included among the top collaborators of Daniël De Vos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniël De Vos. Daniël De Vos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vos, Daniël De, et al.. (2025). Exploring Phage-Antibiotic Synergies in The Context of Biofilm-related Infectious Diseases. International Journal of Infectious Diseases. 152. 107590–107590. 1 indexed citations

Wang, Zhifen, Steven De Soir, Maya Merabishvili, et al.. (2024). Bacteriophages as potential antibiotic potentiators in cystic fibrosis: A new model to study the combination of antibiotics with a bacteriophage cocktail targeting dual species biofilms of Staphylococcus aureus and Pseudomonas aeruginosa. International Journal of Antimicrobial Agents. 64(3). 107276–107276. 3 indexed citations

Merabishvili, Maia, Jean‐Paul Pirnay, & Daniël De Vos. (2023). Guidelines to Compose an Ideal Bacteriophage Cocktail. Methods in molecular biology. 2734. 49–66. 8 indexed citations

Castledine, Meaghan, Daniel Padfield, Pawel Sierocinski, et al.. (2022). Parallel evolution of Pseudomonas aeruginosa phage resistance and virulence loss in response to phage treatment in vivo and in vitro. White Rose Research Online (University of Leeds, The University of Sheffield, University of York). 53 indexed citations

Merabishvili, Maya, Mario Vaneechoutte, Steven De Soir, et al.. (2021). Evaluation of the Stability of Bacteriophages in Different Solutions Suitable for the Production of Magistral Preparations in Belgium. Viruses. 13(5). 865–865. 56 indexed citations

Fauconnier, Alan, et al.. (2020). The Unique Role That WHO Could Play in Implementing Phage Therapy to Combat the Global Antibiotic Resistance Crisis. Frontiers in Microbiology. 11. 1982–1982. 8 indexed citations

Merabishvili, Maya, Jean‐Paul Pirnay, Daniël De Vos, et al.. (2019). Development of a qPCR platform for quantification of the five bacteriophages within bacteriophage cocktail 2 (BFC2). Scientific Reports. 9(1). 13893–13893. 24 indexed citations

Sybesma, Wilbert, Christine H. Rohde, Jean‐Paul Pirnay, et al.. (2018). Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part II. Antibiotics. 7(2). 35–35. 51 indexed citations

Kurtböke, D. İpek, Ian Macreadie, Rustam Aminov, et al.. (2017). Volume 38 Number 2. Microbiology Australia. 38(2). 49–94. 1 indexed citations

10.

Pirnay, Jean‐Paul, et al.. (2017). Bacteriophage Production in Compliance with Regulatory Requirements. Methods in molecular biology. 1693. 233–252. 46 indexed citations

11.

Serrano, Isa, Daniël De Vos, Florence Bilocq, et al.. (2016). Antimicrobial resistance and genomic rep-PCR fingerprints of Pseudomonas aeruginosa strains from animals on the background of the global population structure. BMC Veterinary Research. 13(1). 58–58. 16 indexed citations

12.

Anantharajah, Ahalieyah, Julien M. Buyck, Emmanuel Faure, et al.. (2015). Correlation between cytotoxicity induced byPseudomonas aeruginosaclinical isolates from acute infections and IL-1β secretion in a model of human THP-1 monocytes. Pathogens and Disease. 73(7). ftv049–ftv049. 15 indexed citations

13.

Verbeken, Gilbert, Isabelle Huys, Daniël De Vos, et al.. (2015). Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework. FEMS Microbiology Letters. 363(4). fnv241–fnv241. 9 indexed citations

14.

Verbeken, Gilbert, Isabelle Huys, Jean‐Paul Pirnay, et al.. (2014). Taking Bacteriophage Therapy Seriously: A Moral Argument. BioMed Research International. 2014. 1–8. 32 indexed citations

15.

Pirnay, Jean‐Paul, A. Vanderkelen, Daniël De Vos, et al.. (2013). Business oriented EU human cell and tissue product legislation will adversely impact Member States’ health care systems. Cell and Tissue Banking. 14(4). 525–560. 36 indexed citations

16.

Merabishvili, Maia, Daniël De Vos, Gilbert Verbeken, et al.. (2012). Selection and Characterization of a Candidate Therapeutic Bacteriophage That Lyses the Escherichia coli O104:H4 Strain from the 2011 Outbreak in Germany. PLoS ONE. 7(12). e52709–e52709. 42 indexed citations

17.

Pirnay, Jean‐Paul, A. Vanderkelen, Nadine Ectors, et al.. (2012). Beware of the commercialization of human cells and tissues: situation in the European Union. Cell and Tissue Banking. 13(3). 487–498. 11 indexed citations

18.

Vandersteegen, Katrien, Wesley Mattheus, Pieter‐Jan Ceyssens, et al.. (2011). Microbiological and Molecular Assessment of Bacteriophage ISP for the Control of Staphylococcus aureus. PLoS ONE. 6(9). e24418–e24418. 90 indexed citations

19.

Merabishvili, Maya, Jean‐Paul Pirnay, Gilbert Verbeken, et al.. (2009). Quality-Controlled Small-Scale Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical Trials. PLoS ONE. 4(3). e4944–e4944. 392 indexed citations

20.

Vos, Daniël De, C.L. Vilela, T.L. Pitt, et al.. (2008). Antibiotic Resistance Profiling of Phenotypic and Genomic Characterized Pseudomonas aeruginosa Isolates from Animal and Human Origin. International Journal of Infectious Diseases. 12. e121–e122. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact